1. Assessment of heparin anticoagulation: comparison of two commercially available methods 
Hanne I Flom-Halvorsen, PhD, Eivind Øvrum, MD, PhD, Michel Abdelnoor, PhD, Stine Bjørnsen, Frank Brosstad, MD, PhD 
The Annals of Thoracic Surgery 
Volume 67, Issue 4, Pages (April 1999)
DOI: /S (99)

2. Fig 1
The relationship between the clotting time in seconds of activated clotting time (ACT) and thrombolytic assessment system heparin management test (TAS HMT) methods and the plasma heparin concentration (IU/mL) measured by anti-FXa assay in ten patients who had cardiopulmonary bypass (CPB). The data are presented as mean values.
The Annals of Thoracic Surgery  , DOI: ( /S (99) )

3. Fig 2
Ex vivo study. (A) Regression line between the clotting time (in seconds) of whole blood activated clotting time (ACT). (B) Thrombolytic assessment system heparin management test (TAS HMT) and plasma heparin concentration (IU/mL) measured in samples from ten patients who had cardiopulmonary bypass. The data are corrected for their respective baseline values, and the mean values of the double determinations are used.
The Annals of Thoracic Surgery  , DOI: ( /S (99) )

4. Fig 3
In vitro study. (A) Regression line between the activated clotting time (ACT). (B) thrombolytic assessment system heparin management test (TAS HMT) seconds and measured plasma heparin concentration (IU/mL) in samples from donor whole-blood spiked with known amounts of heparin. The data are corrected for their baseline values and presented as mean values.
The Annals of Thoracic Surgery  , DOI: ( /S (99) )